Pyoderma gangrenosum
Pyoderma gangrenosum bụ ọrịa akpụkpọ anụ na-adịghị ahụkebe ebe ọnya na-egbu mgbu ma ọ bụ nodules na-aghọ ọnya na-eto nke nta nke nta. Pyoderma gangrenosum anaghị efe efe. Ọgwụgwọ nwere ike ịgụnye corticosteroids, cyclosporin, ma ọ bụ ọgwụ mgbochi monoclonal dị iche iche. Ọ bụ ezie na ọ nwere ike imetụta ndị nọ n'afọ ọ bụla, ọ na-emetụtakarị ndị nọ n'afọ 40 na 50.
☆ Na nsonaazụ Stiftung Warentest nke 2022 sitere na Germany, afọ ojuju ndị ahịa na ModelDerm dị ntakịrị ntakịrị karịa na nyocha telemedicine akwụ ụgwọ.
N'ụkwụ onye nwere ulcerative colitis.
References
Pyoderma gangrenosum bụ ọrịa akpụkpọ ahụ na-adịghị ahụkebe nke na-ebute ọnya na-egbu mgbu nwere akụkụ uhie ma ọ bụ purplish. A na-ekewa ya dị ka ọrịa mkpali na ọ bụ akụkụ nke otu a na-akpọ neutrophilic dermatosis. Ihe kpatara pyoderma gangrenosum dị mgbagwoju anya, gụnyere nsogbu na ma ihe mgbochi ebumpụta ụwa na nke na-agbanwe agbanwe na ndị mmadụ na-enwekarị mkpụrụ ndụ ihe nketa. N'oge na-adịbeghị anya, ndị nchọpụta lekwasịrị anya na ntutu isi dị ka ebe nwere ike ịmalite ọrịa ahụ.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum bụ ọrịa akpụkpọ ahụ na-adịghị ahụkebe na-akpata ọnya na-egbu mgbu. Ọ bụ ezie na anyị aghọtachaghị ihe kpatara ya, anyị maara na ọ gụnyere mmụba nke ụfọdụ mkpụrụ ndụ na-alụso ọrịa ọgụ. Ịgwọ ọrịa ahụ adịghịkwa mfe. Anyị nwere ọgwụ dị iche iche na-egbochi usoro ahụ ji alụso ọrịa ọgụ ma ọ bụ gbanwee ọrụ ya. N'akụkụ ndị a, anyị na-elekwasịkwa anya n'ịgwọ ọnya na ịchịkwa mgbu. Corticosteroids na cyclosporine na-abụkarị nhọrọ mbụ maka ọgwụgwọ, mana n'oge na-adịbeghị anya, enweela nyocha ndị ọzọ maka iji usoro ọgwụgwọ dị ndụ dị ka ndị na-emechi TNF-α. A na-enwewanye mmasị na ihe ndị dị ndụ, karịsịa na ndị ọrịa nwere ọnọdụ mkpali ndị ọzọ, a na-ejikwa ha na mbụ na usoro ọrịa ahụ.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
